Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
14 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy - AT
Institution: Information not provided - AT
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Comparison of dosimetry following preparation with either rhTSH or after withdrawal of thyroid hormone suppression therapy in patients with metastatic or locally advanced differentiated thyroid cancer - FR
CLCC Institut Gustave Roussy
Cancers endocriniens - Cancer de la thyroïde
FRANCIA
PAYS DE LA LOIRE
ANGERS
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (Phase III) - FR
CHU d'Angers
Département d'endocrinologie, diabétologie et nutrition
SPAGNA
Cataluña
BARCELONA
The DUTHY Trial: A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPAGNA
Madrid
MADRID
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Oncohematología
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
FRANCIA
AUVERGNE-RHONE-ALPES
LYON
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma (Phase II) - FR
CLCC Léon Bérard
Centre Léon Bérard
REGNO UNITO; GRAN BRETAGNA
Greater Manchester
ADDRESS: NOT PROVIDED - UK
ION - Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients - UK
Institution: Information not provided - UK
SPAGNA
Cataluña
BARCELONA
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (Phase II) - ES
Hospital Universitari Vall d'Hebron
SPAGNA
Madrid
MADRID
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (Phase II) - ES
Hospital Universitario 12 de Octubre
SPAGNA
Madrid
MADRID
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (Phase II) - ES
Hospital Universitario Ramón y Cajal
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
Sperimentazioni cliniche internazionali
GERMANIA
Nordrhein-Westfalen
LEVERKUSEN
STATI UNITI
New Jersey
RAHWAY